Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study

Table 4 Change in total WOMAC score from baseline

Analytical method	Type of analysis	Time point (Days)	Placebo (n = 53)	GC (n = 57)	UC-II (n = 54)	p value (95 % CI)
Analytical method	Type of analysis	Time point (Days)	Placebo (n = 53)	GC (n = 57)	UC-II (n = 54)	Overall^a	GC vs PBO	UC-II vs PBO^b	UC-II vs GC
ANCOVA	mITT	180	−414 ± 28.5	−454 ± 27.5	−551 ± 28.2	0.002	0.56 (−134 to 53)	0.002 (−232 to −42)	0.04^c (−190 to −3)
MMRM	mITT	180	−397 ± 28.6	−452 ± 27.6	−514 ± 28.3	0.014	0.33 (−148 to 37)	0.0097 (−210 to −24)	0.25 (−153 to 30)
			(n = 58)	(n = 65)	(n = 63)
iAUC	ITT	1 to 180	−1479 ± 137	−1751 ± 130	−2042 ± 132	0.014	0.33 (−718 to 174)	0.0098 (−1012 to −113)	0.26 (−727 to 146)

Values presented as Mean ± SE
Abbreviations: PBO placebo
^aOverall p value was obtained by comparing the mean changes among the three groups using ANCOVA
^bSignificant difference between the UC-II and the placebo groups using Tukey-Kramer test
^cSignificant difference between the UC-II and the GC groups using Tukey-Kramer test

ISSN: 1475-2891